Atomo Diagnostics (ASX:AT1) YoY EPS Growth: 33.33% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Atomo Diagnostics YoY EPS Growth?

Atomo Diagnostics ASX:AT1 -7.89% YoY EPS Growth is 33.33% as of Jun. 2026. The stock has 4 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Atomo Diagnostics's YoY EPS Growth for the quarter that ended in Jun. 2026 was 33.33%.

Atomo Diagnostics's Earnings per Share (Diluted) for the six months ended in Jun. 2026 was A$-0.00.

Atomo Diagnostics YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Atomo Diagnostics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atomo Diagnostics YoY EPS Growth Chart

Atomo Diagnostics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
YoY EPS Growth
Get a 7-Day Free Trial 9.09 -70.00 35.29 27.27 50.00

Atomo Diagnostics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.29 20.00 50.00 50.00 33.33

Atomo Diagnostics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Atomo Diagnostics's YoY EPS Growth for the fiscal year that ended in Jun. 2026 is calculated as:

YoY EPS Growth (A: Jun. 2026 )
=(Earnings per Share (Diluted) (A: Jun. 2026 )-Earnings per Share (Diluted) (A: Jun. 2025 ))/ | Earnings per Share (Diluted) (A: Jun. 2025 ) |
=(-0.004--0.008)/ | -0.008 |
=50.00 %

Atomo Diagnostics's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-0.002--0.003)/ | -0.003 |
=33.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 33.33% mean?
Atomo Diagnostics (ASX:AT1) has a YoY EPS Growth of 33.33% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Atomo Diagnostics and its competitors.
Is Atomo Diagnostics' YoY EPS Growth too high?
Atomo Diagnostics' current YoY EPS Growth is 33.33%.
How does Atomo Diagnostics' YoY EPS Growth compare to ABT and SYK?
Atomo Diagnostics' YoY EPS Growth of 33.33% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Medical Devices & Instruments company?
A good YoY EPS Growth depends on the Medical Devices & Instruments industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Atomo Diagnostics and its competitors. Atomo Diagnostics's current YoY EPS Growth is 33.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.03, compared to a current price of A$0.02 — trading 41.7% below its estimated fair value. The current YoY EPS Growth is 33.33%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current YoY EPS Growth is 33.33% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atomo Diagnostics Business Description

Address 3 - 5 George Street, Level 1, Leichhardt, Syndey, NSW, AUS, 2040
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.